Vivimed Labs Limited has informed the Exchange about General Updates
VIVIMEDLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Vivimed Labs has submitted the impact statement for its FY25 audited results, which carry a Qualified Opinion from the auditors with five separate qualifications. The biggest issue is that the company did not book interest expense of about Rs. 574.44 million on its loans because bank confirmations were unavailable. After adjustments, the standalone net loss balloons from Rs. 314.96 million to Rs. 889.40 million, EPS worsens from Rs. (3.80) to Rs. (10.73), and net worth shrinks from Rs. 584.91 million to just Rs. 10.47 million. On a consolidated basis, net worth actually turns negative at Rs. (926.13) million after adjustments. The auditors could not verify bank borrowings of Rs. 3,744.56 million as all loans are classified as NPA, and confirmations are not coming in. Other qualifications relate to unverifiable related party transactions, missing MSME Act disclosures, and Rs. 587.83 million in subsidiary investments not tested for impairment.
This is a serious red flag for shareholders. The company is in clear financial distress — defaulted on bank loans (all NPA), negotiating settlements with lenders, and consolidated net worth turning negative. Expect significant stock price pressure and elevated risk for existing and prospective investors.